---
figid: PMC2963103__nihms238836f1
figlink: /pmc/articles/PMC2963103/figure/F1/
number: F1
caption: Normal biology of the VHL-HIF axis in the setting of (A) normoxia and (B)
  hypoxia. In normoxic conditions, HIFα is hydroxylated on specific proline residues
  by prolyl-hydroxylases. VHL acts as the sensor for these hydroxylated proline residues
  as part of the VHL-E3 ubiquitin ligase. This polyubiquitinates HIFα and marks it
  for degradation by the proteasome. In hypoxic conditions (or in the presence of
  aberrant VHL), HIFα is allowed to accumulate in the cell. (C) It associates with
  HIFβ, and this complex translocates to the nucleus and acts as a transcription factor
  binding to hypoxia response elements and up-regulating oxygen sensitive genes. These
  include vascular endothelial growth factor (VEGF), platelet-derived growth factor
  (PDGF), transforming growth factor alpha (TGFα), glucose transporter-1 (GLUT1),
  carbonic anhydrase IX (CA-IX), erythropoietin (EPO), and others. Examples of certain
  ligands’ receptors are given, including VEGF receptor (VEGFR), PDGF receptor (PDGFR),
  and the receptor for TNFα, epidermal growth factor receptor (EGFR). Shown is the
  downstream signaling for 1 of these receptors, VEGFR, including through the PI3
  kinase (PI3K)/AKT/mTOR, p38 MAP kinase (p38MAPK), and RAS/RAF/MEK/ERK pathways.
  Examples of agents that impact on this cascade are given, and where they act on
  the pathway is shown.
pmcid: PMC2963103
papertitle: The von Hippel-Lindau Gene.
reftext: Peter E. Clark, et al. Cancer. ;113(7 Suppl):1768-1778.
pmc_ranked_result_index: '117484'
pathway_score: 0.8973594
filename: nihms238836f1.jpg
figtitle: Normal biology of the VHL-HIF axis in the setting of (A) normoxia and (B)
  hypoxia
year: ''
organisms:
- Homo sapiens
ndex: 6ef3e98a-df14-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2963103__nihms238836f1.html
  '@type': Dataset
  description: Normal biology of the VHL-HIF axis in the setting of (A) normoxia and
    (B) hypoxia. In normoxic conditions, HIFα is hydroxylated on specific proline
    residues by prolyl-hydroxylases. VHL acts as the sensor for these hydroxylated
    proline residues as part of the VHL-E3 ubiquitin ligase. This polyubiquitinates
    HIFα and marks it for degradation by the proteasome. In hypoxic conditions (or
    in the presence of aberrant VHL), HIFα is allowed to accumulate in the cell. (C)
    It associates with HIFβ, and this complex translocates to the nucleus and acts
    as a transcription factor binding to hypoxia response elements and up-regulating
    oxygen sensitive genes. These include vascular endothelial growth factor (VEGF),
    platelet-derived growth factor (PDGF), transforming growth factor alpha (TGFα),
    glucose transporter-1 (GLUT1), carbonic anhydrase IX (CA-IX), erythropoietin (EPO),
    and others. Examples of certain ligands’ receptors are given, including VEGF receptor
    (VEGFR), PDGF receptor (PDGFR), and the receptor for TNFα, epidermal growth factor
    receptor (EGFR). Shown is the downstream signaling for 1 of these receptors, VEGFR,
    including through the PI3 kinase (PI3K)/AKT/mTOR, p38 MAP kinase (p38MAPK), and
    RAS/RAF/MEK/ERK pathways. Examples of agents that impact on this cascade are given,
    and where they act on the pathway is shown.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BNIP3
  - ARNT2
  - EPAS1
  - ARAF
  - FLT4
  - AKT2
  - HIF1A
  - ARNTL
  - RAF1
  - FLT1
  - AKT1
  - AKT3
  - HIF3A
  - VEGFC
  - MAPK9
  - MAPK14
  - PDGFRB
  - KDR
  - CA9
  - ARNT
  - VEGFB
  - MAPK11
  - PDGFA
  - MTOR
  - PDGFC
  - PDGFRA
  - BRAF
  - MAPK1
  - MAPK3
  - SLC2A1
  - VEGFA
  - MAP2K1
  - MAP2K2
  - TGFA
  - PDGFB
  - PDGFD
  - NRAS
  - HRAS
  - EGFR
  - EPO
  - MAPKAPK3
  - MAPKAPK2
  - VEGFD
  - PGF
  - MAPK8
  - KRAS
  - VHL
  - MAPK12
  - MAPK10
  - MAPK13
  - Temsirolimus
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: BNIP3
  symbol: BNIP3
  source: hgnc_symbol
  hgnc_symbol: BNIP3
  entrez: '664'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT2
  entrez: '9915'
- word: HIFA
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: HIFA
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNTL
  entrez: '406'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: PDGFR.
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: CA-IX
  symbol: CAIX
  source: hgnc_alias_symbol
  hgnc_symbol: CA9
  entrez: '768'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT
  entrez: '405'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFA
  entrez: '5154'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFC
  entrez: '56034'
- word: PDGFR.
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: HIFA
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: GLUT1
  symbol: GLUT1
  source: hgnc_prev_symbol
  hgnc_symbol: SLC2A1
  entrez: '6513'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: TGFA
  symbol: TGFA
  source: hgnc_symbol
  hgnc_symbol: TGFA
  entrez: '7039'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFD
  entrez: '80310'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: EPO
  symbol: EPO
  source: hgnc_symbol
  hgnc_symbol: EPO
  entrez: '2056'
- word: MAPKAPK2/3
  symbol: MAPKAPK3
  source: hgnc_symbol
  hgnc_symbol: MAPKAPK3
  entrez: '7867'
- word: MAPKAPK2/3
  symbol: MAPKAPK2
  source: hgnc_symbol
  hgnc_symbol: MAPKAPK2
  entrez: '9261'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: VHL
  symbol: VHL
  source: hgnc_symbol
  hgnc_symbol: VHL
  entrez: '7428'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
chemicals:
- word: Temsirolimus
  source: MESH
  identifier: C401859
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC2963103__F1
redirect_from: /figures/PMC2963103__F1
figtype: Figure
---
